Literature DB >> 10966936

Mechanism of increases in L-kynurenine and quinolinic acid in renal insufficiency.

K Saito1, S Fujigaki, M P Heyes, K Shibata, M Takemura, H Fujii, H Wada, A Noma, M Seishima.   

Abstract

Marked increases in metabolites of the L-tryptophan-kynurenine pathway, L-kynurenine and quinolinic acid (Quin), were observed in serum and cerebrospinal fluid (CSF) of both the rat and human with renal insufficiency. The mechanisms responsible for their accumulation after renal insufficiency were investigated. In patients with chronic renal insufficiency, elevated levels of serum L-kynurenine and Quin were reduced by hemodialysis. In renal-insufficient rats, Quin and L-kynurenine levels in serum, brain, and CSF were also increased parallel to the severity of renal insufficiency. Urinary excretion of Quin (3.5-fold) and L-kynurenine (2.8-fold) was also increased. Liver L-tryptophan 2,3-dioxygenase activity (TDO), a rate-limiting enzyme of the kynurenine pathway, was increased in proportion to blood urea nitrogen and creatinine levels. Kynurenine 3-hydroxylase and quinolinic acid phosphoribosyltransferase were unchanged, but the activities of kynureninase, 3-hydroxyanthranilate dioxygenase, and aminocarboxymuconate-semialdehyde decarboxylase (ACMSDase) were significantly decreased. Systemic administrations of pyrazinamide (ACMSDase inhibitor) increased serum Quin concentrations in control rats, demonstrating that changes in body ACMSDase activities in response to renal insufficiency are important factors for the determination of serum Quin concentrations. We hypothesize the following ideas: that increased serum L-kynurenine concentrations are mainly due to the increased TDO and decreased kynureninase activities in the liver and increased serum Quin concentrations are due to the decreased ACMSDase activities in the body after renal insufficiency. The accumulation of CSF L-kynurenine is caused by the entry of increased serum L-kynurenine, and the accumulation of CSF Quin is secondary to Quin from plasma and/or Quin precursor into the brain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10966936     DOI: 10.1152/ajprenal.2000.279.3.F565

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  46 in total

1.  Accumulation of toxic products degradation of kynurenine in hemodialyzed patients.

Authors:  D Pawlak; K Pawlak; J Malyszko; M Mysliwiec; W Buczko
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  Purification and molecular cloning of rat 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase.

Authors:  Atsushi Tanabe; Yukari Egashira; Shin-Ichi Fukuoka; Katsumi Shibata; Hiroo Sanada
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

3.  Anthranilic acid-uraemic toxin damaged red cell's membrane.

Authors:  A Tankiewicz; D Pawlak; K Pawlak; D Szewc; M Myśliwiec; W Buczko
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

4.  Kynurenic acid and alcohol and cocaine dependence: novel effects and multiple mechanisms?

Authors:  Abdulla A-B Badawy
Journal:  Psychopharmacology (Berl)       Date:  2016-11-24       Impact factor: 4.530

5.  Kynurenine aminotransferase III and glutamine transaminase L are identical enzymes that have cysteine S-conjugate β-lyase activity and can transaminate L-selenomethionine.

Authors:  John T Pinto; Boris F Krasnikov; Steven Alcutt; Melanie E Jones; Thambi Dorai; Maria T Villar; Antonio Artigues; Jianyong Li; Arthur J L Cooper
Journal:  J Biol Chem       Date:  2014-09-17       Impact factor: 5.157

6.  Validation of a Metabolite Panel for a More Accurate Estimation of Glomerular Filtration Rate Using Quantitative LC-MS/MS.

Authors:  Tiffany A Freed; Josef Coresh; Lesley A Inker; Douglas R Toal; Regis Perichon; Jingsha Chen; Kelli D Goodman; Qibo Zhang; Jessie K Conner; Deirdre M Hauser; Kate E T Vroom; Maria L Oyaski; Jacob E Wulff; Gudný Eiríksdóttir; Vilmundur Gudnason; Vicente E Torres; Lisa A Ford; Andrew S Levey
Journal:  Clin Chem       Date:  2019-01-15       Impact factor: 8.327

7.  Activation of the Serotonin Pathway is Associated with Poor Outcome in COPD Exacerbation: Results of a Long-Term Cohort Study.

Authors:  Marc A Meier; Manuel Ottiger; Alaadin Vögeli; Christian Steuer; Luca Bernasconi; Robert Thomann; Mirjam Christ-Crain; Christoph Henzen; Claus Hoess; Werner Zimmerli; Andreas Huber; Beat Mueller; Philipp Schuetz
Journal:  Lung       Date:  2017-04-22       Impact factor: 2.584

8.  Clinical and metabolomic risk factors associated with rapid renal function decline in sickle cell disease.

Authors:  Julia Z Xu; Melanie E Garrett; Karen L Soldano; Sean T Chen; Clary B Clish; Allison E Ashley-Koch; Marilyn J Telen
Journal:  Am J Hematol       Date:  2018-09-27       Impact factor: 10.047

9.  A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study.

Authors:  D Theofylaktopoulou; Ø Midttun; A Ulvik; P M Ueland; G S Tell; S E Vollset; O Nygård; S J P M Eussen
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

10.  Indoleamine 2,3-dioxygenase expression promotes renal ischemia-reperfusion injury.

Authors:  Kanishka Mohib; Shuang Wang; Qiunong Guan; Andrew L Mellor; Hongtao Sun; Caigan Du; Anthony M Jevnikar
Journal:  Am J Physiol Renal Physiol       Date:  2008-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.